The valves of the system are implanted percutaneously into the right atrium. Credit: Jo Panuwat D / Shutterstock.com.

The US Food and Drug Administration (FDA) has granted approval to P&F USA to begin the randomised, controlled TRICAV II pivotal trial of the TricValve transcatheter bicaval valve system for individuals with severe tricuspid regurgitation (TR) and right heart failure (RHF).

The study compares the system with optimal medical therapy (OMT) against only OMT.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

TricValve is a minimally invasive treatment and has secured a breakthrough device designation, offering a treatment pathway for those who do not have surgical or transcatheter alternatives which are commercially available.

P&F USA is the subsidiary of Austria-based P&F Products and Features, a heart valve manufacturer.

The US regulator previously granted authorisation for the early feasibility trial, TRICAV I, assessing the system in 110 individuals at 50 sites in the US.

In December 2024, the FDA approved the TRICAV I’s system expansion from 15 to 50 patients at 50 US sites via the investigational device exemption (IDE) G240065.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The system has received CE Mark and is available in approximately 70 nations, with more than 3,000 patients receiving the treatment.

According to P&F USA, severe TR is linked with progressive RHF, diminished quality of life, and frequent hospitalisations.

Comprising two biological, self-expanding valves, the system is intended to address haemodynamically significant tricuspid insufficiency and caval reflux.

P&F USA noted that the system is a heterotopic solution in which the valves are implanted percutaneously into the right atrium and secured using long stents placed in the vena cava.

P&F co-founder and CEO Katharina Kiss, alongside COO and president Siegfried Einhellig, said: “The TRICAV II pivotal trial offers new hope for patients with severe TR who currently have no suitable surgical or transcatheter treatment options.

“The TricValve system was developed specifically to address this underserved population with a safe, minimally invasive solution.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact